Literature DB >> 32926091

Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D.

Colette DeJong1, Camlyn Masuda2, Randi Chen3, Dhruv S Kazi4, R Adams Dudley5, Chien-Wen Tseng3,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32926091      PMCID： PMC7490744          DOI： 10.1001/jamainternmed.2020.2922

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  3 in total

1.  Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States.

Authors:  Veer Sangha; Kasia Lipska; Zhenqiu Lin; Silvio E Inzucchi; Darren K McGuire; Harlan M Krumholz; Rohan Khera
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2021-11-15

2.  Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: A population-based study.

Authors:  Beini Lyu; Alex R Chang; Lesley A Inker; Elizabeth Selvin; Morgan E Grams; Jung-Im Shin
Journal:  Lancet Reg Health Am       Date:  2022-04-02

3.  Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure.

Authors:  Birju R Rao; Candace D Speight; Larry A Allen; Scott D Halpern; Yi-An Ko; Daniel D Matlock; Miranda A Moore; Alanna A Morris; Laura D Scherer; Mary C Thomson; Peter Ubel; Neal W Dickert
Journal:  J Am Heart Assoc       Date:  2022-06-20       Impact factor: 6.106
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.